← ANALYST RATINGS · TIPRANKS
Xeris Pharmaceuticals (XERS): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy1 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $13.00, the highest $18.00, the lowest $8.00. The average is +26.1% from the last price of $10.31.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $11.00 → $11.50+4.5% | Buy | +11.5% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $10.50 → $11.00+4.8% | Hold | +6.7% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $10.50 → $11.00+4.8% | Hold | +6.7% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $10.50 → $11.00+4.8% | Hold | +6.7% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $10.50 → $11.50+9.5% | Buy | +11.5% | Upgrade | 14.10.26on TipRanks 16:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $10.50 → $11.00+4.8% | Hold | +6.7% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| Jenna Davidner★★★★★★★★★★#10265 · hits 25% · avg −5.3% | Barclays | $12.00 → $14.00+16.7% | Buy | +35.8% | Reiterated | 06.10.26on TipRanks 04:50 | −1.1%next day +0.6% · 5 days +1.4% | ↗ |
| Chase Knickerbocker★★★★★★★★★★#75 · hits 59% · avg +36.2% | Craig-Hallum | $12.00 | Buy | +16.4% | Reiterated | 29.09.26on TipRanks 09:50 | +1.7%next day −4.0% · 5 days −1.0% | ↗ |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | $10.00 | Buy | −3.0% | Reiterated | 21.09.26on TipRanks 13:55 | +5.8%next day −0.8% · 5 days +12.7% | ↗ |
| Unknown Analyst | Oppenheimer | $18.00 | Buy | +74.6% | Reiterated | 10.09.26on TipRanks 07:50 | +0.1%next day −3.7% · 5 days +5.8% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $8.00 | Hold | −22.4% | Reiterated | 10.09.26on TipRanks 07:10 | +0.1%next day −3.7% · 5 days +5.8% | ↗ |
| Roanna Ruiz★★★★★★★★★★#9351 · hits 46% · avg −0.3% | Leerink Partners | $12.00 → $16.00+33.3% | Buy | +55.2% | Reiterated | 10.09.26on TipRanks 06:15 | +0.1%next day −3.7% · 5 days +5.8% | ↗ |
| Unknown Analyst | Jefferies | $10.00 | Buy | −3.0% | Reiterated | 09.01.26on TipRanks 11:00 | −3.1%next day −0.9% · 5 days −4.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Xeris Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $12.67 at a price of $9.56 (+32.5%); now: $13.00 at $10.31 (+26.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 4 | 3 | 1 | 4 | 4 |
| Buy | 2 | 3 | 4 | 5 | 6 | 6 |
| Hold | 0 | 0 | 0 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.03 (from $0.01 to $0.06). Last quarter: $-0.18.
Sales
Next quarter’s sales estimate — $102M (from $100M to $103M). Last quarter: $92M.
Best top-analyst consensus in the sector · Healthcare
About Xeris Pharmaceuticals
- CEO: John Shannon
- Employees: 435
- 1375 West Fulton Street, Chicago, IL, 60607, US
- www.xerispharma.com
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Data from the stock’s TipRanks forecast page, read 60 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗